[Prostaglandin E2 in prostatitis and prostatic adenoma].
The measurement of prostaglandin E2 (PGE2) concentrations in the serum and prostatic fluid of healthy men, patients with prostatic hyperplasia and of patients with prostatitis was attempted and correlated to the state of disease, respectively. PGE2-concentrations with prostatic fluid of healthy men were found to be significantly lower than in patients with prostatitis. Corresponding to the course of treatment concentrations normalized, being favorably influenced by sitosterin as an adjuvant medication. Compared to healthy men, PGF2 concentrations in the prostatic fluid of patients with hyperplasia of the prostate incline to lower levels.
D000328:Adult; D002908:Chronic Disease; D015232:Dinoprostone; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D011458:Prostaglandins E / Q000097:blood*; D011467:Prostate / Q000378:metabolism; D011470:Prostatic Hyperplasia / Q000097:blood* / Q000188:drug therapy; D011472:Prostatitis / Q000097:blood* / Q000188:drug therapy; D011863:Radioimmunoassay; D012855:Sitosterols / Q000627:therapeutic use
D011458:Prostaglandins E; D012855:Sitosterols; C025473:gamma-sitosterol; D015232:Dinoprostone
Prostaglandin E2 bei Prostatitis und Prostataadenom.